MedTrace Logo

A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

NCT06803823 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-05-12

No results posted yet for this study

Summary

To evaluate the efficacy and safety of ONO-2020 in patients with agitation associated with Alzheimer's Disease dementia in Japan.

Conditions

  • Agitation Associated With Alzheimer's Disease Dementia

Interventions

DRUG

ONO-2020

ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily.

DRUG

Placebo

Two ONO-2020 placebo tablets will be orally administered once daily

Sponsors & Collaborators

Principal Investigators

  • Project Leader · Ono Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06803823 on ClinicalTrials.gov